Humanigen launches Managed Access Program for lenzilumab

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company specializing in the prevention and treatment of an overactive immune response called “cytokine shock,” today announced that lenzilumab is now available for select patients. patients with COVID-19 through its new Managed Access Program (“LenzMAP™”). Clinigen Group plc (“Clinigen”), a global pharmaceuticals and services company, is currently implementing…

Read More

It is only thanks to the disposals of wind farms in Brazil that Voltalia has managed to meet its objectives in 2021

The march was high for Voltalia, after a disappointing first half, to be able to meet its 2021 objectives. But thanks to strong growth in its turnover in the fourth quarter (+90% to 158 million euros), the producer of green electricity has kept its commitments. “Assignments save guidance”sums up the financial analyst Nicolas Royot of…

Read More